Zhonghua zhong liu za zhi [Chinese journal of oncology]HumansImmunotherapyAdoptiveAntigensCD19
[Expert consensus on the management practice of CD19 CAR-T cell therapy for B-cell lymphoma in China (2025 edition)].
National Cancer Center, Lymphoma Expert Committee of National Cancer Quality Control Center
Published: 202510.3760/cma.j.cn112152-20250626-00296
Abstract
In recent years, the incidence of B-cell non-Hodgkin lymphoma (B-NHL) in China has shown a steady increase, accounting for approximately 85%-90% of all lymphomas. Although standard immunochemotherapy regimens such as R-CHOP have led to long-term remi…
Preview only. Read the full abstract at the source